Interpace Diagnostics

Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test, ThyGenX, an expanded oncogenic mutation panel that helps identify malignant thyroid nodules, ThyraMIR, which assesses thyroid nodules for risk of malignancy, and RespriDx, a genomic test that helps physicians differentiate metastatic or recurrent lung cancer. The company was founded by John P. Dugan in 1986 and is headquartered in Parsippany, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PARSIPPANY, NJ, Oct.  15, 2019  (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silicon Review. The honorees are chosen by The Silicon Review’s editorial board recognizing companies whose industry achievements break new technological ground and who’s company cultures and values represent a commitment to innovation.

Interpace Named to ‘Most Admired Companies’ List

In-Network Access for Thyroid Assays for More than 5 Million Members

Interpace Announces New Contracts with Multiple Blue Cross Blue Shield Plans

PARSIPPANY, NJ, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming Ladenburg Thalmann 2019 Healthcare Conference, held on September 24th, 2019 at the Sofitel hotel in New York City, NY. Jack Stover, President and CEO of Interpace, will provide an overview of the business and will be available to participate in one-on-one meetings with investors and analysts who are registered to attend the conference.

Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference

PARSIPPANY, NJ, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC. According to the agreement, Interpace BioPharma will perform services worldwide except in the PRC, while Genecast will provide services in the PRC.

Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China

PARSIPPANY, NJ, Sept.  06, 2019  (GLOBE NEWSWIRE) -- ﻿Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming 21st Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., held September 8 - 10, 2019 at the Lotte New York Palace Hotel. Jack Stover, President and CEO of Interpace, will provide an overview of the business and will be available to participate in one-on-one meetings with investors and analysts who are registered to attend the conference.

Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q2 2019 Results - Earnings Call Transcript

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q1 2019 Results - Earnings Call Transcript

Interpace Diagnostics Group, Inc. (IDXG) CEO Jack Stover on Q4 2018 Results - Earnings Call Transcript

News for Interpace Diagnostics Stock (IDXG)